TQJ230, INCLISIRAN, Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device
CTQJ230A12304
Phase 3 small_molecule active
Quick answer
TQJ230, INCLISIRAN, Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device for Atherosclerotic cardiovascular disease (ASCVD) is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Atherosclerotic cardiovascular disease (ASCVD)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active